Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.

[1]  M. Piver,et al.  Familial ovarian cancer: A report of 658 families from the gilda radner familial ovarian cancer registry 1981–1991 , 2010 .

[2]  T. Rebbeck,et al.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. , 2002, Journal of the National Cancer Institute.

[3]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[4]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[5]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[6]  J. Satagopan,et al.  Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Morice,et al.  Prophylactic surgery in patients with inherited risk of ovarian cancer. , 2001, Gynecologic oncology.

[8]  C. Burger,et al.  Occult cancer in the fallopian tube in patients with a BRCA-1 germline mutation. , 2001, Gynecologic oncology.

[9]  J. Klijn,et al.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[10]  C. Isaacs,et al.  Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study , 2001, The Lancet.

[11]  J. Satagopan,et al.  Risk of endometrial carcinoma associated with BRCA mutation. , 2001, Gynecologic oncology.

[12]  J. Klijn,et al.  Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Lynch,et al.  Current status of prophylactic surgery for hereditary breast and gynecologic cancers , 2001, Current opinion in obstetrics & gynecology.

[14]  Rochelle L. Garcia,et al.  Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. , 2001, Gynecologic oncology.

[15]  D. Easton,et al.  Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. , 2001, American journal of human genetics.

[16]  R. Knapp,et al.  Long-term follow-up of the Stockholm screening study on ovarian cancer. , 2000, Gynecologic oncology.

[17]  T. Bourne,et al.  Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group , 2000, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[18]  Yoshiharu Saito,et al.  Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography , 2000 .

[19]  E. Levy-Lahad,et al.  BRCA1 Germline Mutations in Women With Uterine Serous Papillary Carcinoma , 2000, Obstetrics and gynecology.

[20]  P. Devilee,et al.  Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation , 2000, The Lancet.

[21]  E J Pavlik,et al.  The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. , 2000, Gynecologic oncology.

[22]  T. Rebbeck,et al.  Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Wiesner,et al.  Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. , 2000, Gynecologic oncology.

[24]  K. Heimdal,et al.  Prospectively detected cancer in familial breast/ovarian cancer screening , 1999, Acta obstetricia et gynecologica Scandinavica.

[25]  Steven J Skates,et al.  Screening for ovarian cancer: a pilot randomised controlled trial , 1999, The Lancet.

[26]  R. L. Baldwin,et al.  Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. , 1999, American journal of obstetrics and gynecology.

[27]  P. Kenemans,et al.  CA 125: fundamental and clinical aspects. , 1999, Seminars in cancer biology.

[28]  T. Sheldon,et al.  The performance of screening tests for ovarian cancer: results of a systematic review , 1998, British Journal of Obstetrics and Gynaecology.

[29]  B. Ponder,et al.  Oral Contraceptives and the Risk of Hereditary Ovarian Cancer , 1998 .

[30]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[31]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[32]  E. Thomson,et al.  Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2 , 1997 .

[33]  K Offit,et al.  Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. , 1997, JAMA.

[34]  A S Whittemore,et al.  Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. , 1997, American journal of human genetics.

[35]  M. Piver,et al.  Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. , 1996, The oncologist.

[36]  R. Bast,et al.  Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers , 1995, Cancer.

[37]  R. Bast,et al.  Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection , 1995, Cancer.

[38]  A. Whittemore,et al.  Risks of cancer among members of families in the gilda radner familial ovarian cancer registry , 1995, Cancer.

[39]  Robert C. Bast,et al.  Ovarian cancer: screening, treatment, and followup. , 1995, NIH consensus statement.

[40]  T. Bourne,et al.  Feasibility Study of a Randomised Trial of Ovarian Cancer Screening among the General Population , 1994, Journal of medical screening.

[41]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[42]  R. Bast,et al.  Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15‐3 and TAG 72.3 , 1993, British journal of obstetrics and gynaecology.

[43]  E J Pavlik,et al.  A morphology index based on sonographic findings in ovarian cancer. , 1993, Gynecologic oncology.

[44]  R. Berkowitz,et al.  Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. , 1993, Gynecologic oncology.

[45]  T. Bourne,et al.  Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. , 1993, BMJ.

[46]  M. Quinn,et al.  The effect of the menstrual cycle on serum CA 125 levels: a population study. , 1992, American journal of obstetrics and gynecology.

[47]  M. Quinn,et al.  Factors Influencing Serum CA 125 Levels in Normal Women , 1992, Obstetrics and gynecology.

[48]  M. Piver,et al.  Familial ovarian cancer. , 1979, Gynecologic oncology.

[49]  W. Foulkes,et al.  Fallopian tube cancer in a BRCA1 mutation carrier: rapid development and failure of screening. , 2002, American journal of obstetrics and gynecology.

[50]  Piver Ms.  The Gilda Radner Familial Ovarian Cancer Registry 1981-2000. , 2000 .

[51]  P. V. van Diest,et al.  Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. , 2000, Gynecologic oncology.

[52]  A. Kurjak,et al.  Three-dimensional ultrasound and power doppler improve the diagnosis of ovarian lesions. , 2000, Gynecologic oncology.

[53]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[54]  B. Ponder,et al.  Prophylactic oophorectomy in inherited breast/ovarian cancer families. , 1995, Journal of the National Cancer Institute. Monographs.

[55]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.